Siga Technologies Inc is a biotechnology company focused on developing solutions for public health threats, particularly through its innovative antiviral therapeutics. The company's primary emphasis is on the advancement of treatments for viral infections, with a notable concentration on smallpox and other serious infectious diseases. By leveraging its proprietary technologies, Siga aims to address unmet medical needs and improve health outcomes, especially in the face of potential bioterrorism threats or emerging viral outbreaks. Through collaborations with government entities and investment in research, the company endeavors to enhance global health security and preparedness through effective medical interventions.
SIGA Technologies secures a $9 million DoD contract for TPOXX, boosting total outstanding orders to $154 million. Recent BARDA and DoD wins reinforce growth despite challenges in a key mpox trial.
Several healthcare stocks associated with mpox are seeing increased attention Thursday after the World Health Organization declared a public health emergency in response to an mpox outbreak in Africa.
Russell 2000 ETF (ARCA: IWM) up 2.7%, its strongest session in a month, driven by positive economic data & increased consumer spending, boosting confidence in US economy.
"NIH's NIAID reveals results from the PALM 007 trial of SIGA Technologies' Tpoxx for monkeypox (mpox) treatment. The study missed its primary endpoint but showed potential benefits in early and severe cases. Learn more about the safety profile and market impact on SIGA stock.
Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24 insurance revenue guidance.
